MA46661A - Formulations de vaccin glycoconjugué dirigé contre expec - Google Patents

Formulations de vaccin glycoconjugué dirigé contre expec

Info

Publication number
MA46661A
MA46661A MA046661A MA46661A MA46661A MA 46661 A MA46661 A MA 46661A MA 046661 A MA046661 A MA 046661A MA 46661 A MA46661 A MA 46661A MA 46661 A MA46661 A MA 46661A
Authority
MA
Morocco
Prior art keywords
directed against
vaccine formulations
glycoconjugate vaccine
against expec
formulations directed
Prior art date
Application number
MA046661A
Other languages
English (en)
Other versions
MA46661B1 (fr
Inventor
Janik Adriaansen
Francesco Doro
Olga Labovitiadi
Wouter Frank Tonnis
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MA46661A publication Critical patent/MA46661A/fr
Publication of MA46661B1 publication Critical patent/MA46661B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA46661A 2016-10-24 2017-10-24 Formulations de vaccin glycoconjugué dirigé contre expec MA46661B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16195256 2016-10-24
PCT/EP2017/077123 WO2018077853A1 (fr) 2016-10-24 2017-10-24 Formulations de vaccin glycoconjugué dirigé contre expec

Publications (2)

Publication Number Publication Date
MA46661A true MA46661A (fr) 2019-08-28
MA46661B1 MA46661B1 (fr) 2024-02-29

Family

ID=57206056

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46661A MA46661B1 (fr) 2016-10-24 2017-10-24 Formulations de vaccin glycoconjugué dirigé contre expec

Country Status (26)

Country Link
US (5) US10159751B2 (fr)
EP (1) EP3528839B1 (fr)
JP (1) JP6698220B2 (fr)
KR (1) KR102576346B1 (fr)
CN (1) CN109996559A (fr)
AR (1) AR109621A1 (fr)
AU (1) AU2017349163B2 (fr)
BR (1) BR112019007803A2 (fr)
CA (1) CA3038705A1 (fr)
CL (1) CL2019001104A1 (fr)
CO (1) CO2019003949A2 (fr)
EA (1) EA201991033A1 (fr)
ES (1) ES2966895T3 (fr)
HR (1) HRP20240171T1 (fr)
HU (1) HUE065328T2 (fr)
IL (1) IL266080B (fr)
MA (1) MA46661B1 (fr)
MX (2) MX2019004689A (fr)
MY (1) MY191842A (fr)
PH (1) PH12019500561B1 (fr)
PL (1) PL3528839T3 (fr)
RS (1) RS65125B1 (fr)
SG (1) SG11201902567WA (fr)
TW (1) TWI734853B (fr)
WO (1) WO2018077853A1 (fr)
ZA (1) ZA201902563B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2945651T (pt) 2013-01-17 2018-06-12 Arsanis Biosciences Gmbh Anticorpo específico para mdr e. coli
AU2015220723C1 (en) 2014-02-24 2018-04-05 Glaxosmithkline Biologicals Sa Novel polysaccharide and uses thereof
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
EP3941516A1 (fr) * 2019-03-18 2022-01-26 Janssen Pharmaceuticals, Inc. Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers
AU2021342797B2 (en) * 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
EP4281108A1 (fr) 2021-04-08 2023-11-29 Janssen Pharmaceuticals, Inc. Procédé de production de bioconjugués
EP4478050A1 (fr) 2023-06-12 2024-12-18 Janssen Pharmaceuticals, Inc. Procédé de quantification d'acétate lié dans des glycoconjugués

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
FI102976B1 (fi) 1994-02-28 1999-03-31 Valtion Teknillinen Menetelmä lisäkeittokemikaalien tuottamiseen ja käyttämiseen sulfaattiprosessissa
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
EP1278548A2 (fr) 2000-04-18 2003-01-29 Endobiologics, Incorporated Vaccin conjugue anti-sepsie
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
PT1481057E (pt) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
BRPI0311959B8 (pt) * 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
BRPI0412029A (pt) * 2003-06-30 2006-09-05 Alza Corp formulações para microprojeções revestidas contendo contra-ìons não-voláteis
CN1950397B (zh) 2004-03-30 2012-05-16 Ns基因公司 生长因子NsG33的治疗用途
MXPA06014079A (es) * 2004-06-01 2007-02-15 Ares Trading Sa Metodo para estabilizar proteinas.
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
DE602006017207D1 (de) 2005-05-11 2010-11-11 Eth Zuerich Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
WO2007109813A1 (fr) 2006-03-23 2007-09-27 Novartis Ag Composés d'imidazoquinoxaline utilisés en tant qu'immunomodulateurs
EP2007765B1 (fr) 2006-03-23 2012-06-27 Novartis AG Composes de potentialisation immunitaire
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
EP3124497B1 (fr) 2007-09-14 2020-04-15 Adimab, LLC Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
AU2009215341B2 (en) 2008-02-20 2015-03-26 Glaxosmithkline Biologicals S.A. Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
EP3461840A1 (fr) 2009-04-27 2019-04-03 Immuron Limited Préparation d'immunoglobuline enrichie en anti-lps destinée au traitement et/ou à la prophylaxie de la stéatohépatite non alcoolique
EP2475393A4 (fr) * 2009-09-14 2013-08-21 Vu Truong-Le Formulation pour la stabilisation à température ambiante d'un vaccin bactérien atténué vivant
TR201803015T4 (tr) 2009-11-19 2018-03-21 Glaxosmithkline Biologicals Sa Prokaryotik hücrelerde immünojenik polisakaridler üreten biyosentetik sistem.
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
BR112013005049A2 (pt) * 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
CA2819366A1 (fr) 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Nouvelles formulations reduisant l'aggregation induite par l'agitation de compositions immunogenes
ES2639122T3 (es) * 2011-05-13 2017-10-25 Zoetis Services Llc Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
JP2014526449A (ja) 2011-09-06 2014-10-06 グリコヴァキシン アーゲー 原核細胞において製造されるバイオコンジュゲートワクチン
EP2755994A2 (fr) * 2011-09-14 2014-07-23 Novartis AG Vaccins combinés contre escherichia coli
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
AU2013311534A1 (en) 2012-09-10 2015-03-12 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
WO2014102265A1 (fr) 2012-12-27 2014-07-03 Glycovaxyn Ag Procédés et compositions se rapportant à crm197
PT2945651T (pt) 2013-01-17 2018-06-12 Arsanis Biosciences Gmbh Anticorpo específico para mdr e. coli
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
KR20150132332A (ko) * 2013-03-15 2015-11-25 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 저농도 항체 제형
KR20160062169A (ko) 2013-10-11 2016-06-01 글리코박신 아게 숙주 세포 변형 방법
PT3096785T (pt) * 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
CA2935532A1 (fr) 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh Sequences d'anticorps specifiques diriges contre e. coli
AU2015220723C1 (en) 2014-02-24 2018-04-05 Glaxosmithkline Biologicals Sa Novel polysaccharide and uses thereof
DK3240895T3 (da) 2014-12-30 2022-04-11 Glaxosmithkline Biologicals Sa Sammensætninger og fremgangsmåder til proteinglykosylering
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
EP3941516A1 (fr) 2019-03-18 2022-01-26 Janssen Pharmaceuticals, Inc. Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers

Also Published As

Publication number Publication date
TW201817443A (zh) 2018-05-16
US10159751B2 (en) 2018-12-25
US10525145B2 (en) 2020-01-07
AR109621A1 (es) 2018-12-26
US11033633B2 (en) 2021-06-15
ES2966895T3 (es) 2024-04-24
US20200101167A1 (en) 2020-04-02
CO2019003949A2 (es) 2019-07-31
EP3528839A1 (fr) 2019-08-28
US20190105402A1 (en) 2019-04-11
IL266080B (en) 2022-05-01
JP2019535678A (ja) 2019-12-12
AU2017349163B2 (en) 2019-10-31
KR20190101954A (ko) 2019-09-02
US20210275681A1 (en) 2021-09-09
MA46661B1 (fr) 2024-02-29
CA3038705A1 (fr) 2018-05-03
CL2019001104A1 (es) 2019-06-21
PH12019500561A1 (en) 2019-11-25
PH12019500561B1 (en) 2023-12-06
EP3528839C0 (fr) 2023-11-08
SG11201902567WA (en) 2019-05-30
BR112019007803A2 (pt) 2019-09-03
JP6698220B2 (ja) 2020-05-27
MX2019004689A (es) 2019-11-18
KR102576346B1 (ko) 2023-09-07
MX2023004834A (es) 2023-05-10
AU2017349163A1 (en) 2019-04-11
HRP20240171T1 (hr) 2024-04-12
WO2018077853A1 (fr) 2018-05-03
EA201991033A1 (ru) 2019-09-30
MY191842A (en) 2022-07-18
EP3528839B1 (fr) 2023-11-08
ZA201902563B (en) 2024-09-25
HUE065328T2 (hu) 2024-05-28
NZ751736A (en) 2021-07-30
US11844766B2 (en) 2023-12-19
TWI734853B (zh) 2021-08-01
IL266080A (en) 2019-06-30
US20180110870A1 (en) 2018-04-26
US20240082412A1 (en) 2024-03-14
RS65125B1 (sr) 2024-02-29
CN109996559A (zh) 2019-07-09
PL3528839T3 (pl) 2024-03-25

Similar Documents

Publication Publication Date Title
MA43762A (fr) Vaccin contre le rsv
MA46766A (fr) Vaccin antigrippal
EP3668541A4 (fr) Formulations de vaccin pneumococcique conjugué
HRP20251619T1 (hr) Formulacije pneumokoknih konjugiranih cjepiva
EP3364981A4 (fr) Vaccin contre le cytomégalovirus humain
EP3364950A4 (fr) Vaccins contre des maladies tropicales
DK3393510T5 (da) Zikavirusvaccine
ZA201902563B (en) Expec glycoconjugate vaccine formulations
IL256118A (en) Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
EP4233846C0 (fr) Formulations pharmaceutiques
DK3313436T3 (da) Multivalent pneumokok-konjugatvaccine
DK3603619T3 (da) Vaccineadjuvansformulering
EP3004348A4 (fr) Vaccin contre le paludisme
DK3558391T3 (da) Immunkonjugater med adam9 som mål og fremgangsmåder til anvendelse deraf
MA45381A (fr) Formulation de vaccin contre le vih
IL251120A0 (en) Immunogenic/therapeutic glycoside preparations and their uses
EP3560512A4 (fr) Composition de vaccin contre le zona
EP3405475A4 (fr) Vaccin contre les opioïdes de synthèse
DK3355933T3 (da) Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser
DK3280447T3 (da) Farmaceutiske formuleringer
MA50068A (fr) Formulations de copanlisib
MA47122A (fr) Vaccin à adn multi-épitope contre la cowdriose
EP3439693A4 (fr) Nouvelles formulations de vaccin antipneumococcique
EP3540057A4 (fr) Vaccin antipaludique
GB201615427D0 (en) Francisella glycoconjugate vaccines